CA 125 and OA 3 as target antigens for immunodiagnosis and immunotherapy in ovarian cancer

References

1. • Kenemans P
   • Verheijen RHM
   • Leloux AM
   • Poels LG
   Prospects and applications of monoclonal antibodies in gynecological oncology.
   Eur J Obstet Gynecol Reprod Biol. 1985; 19: 340-346
   • Google Scholar
2. • Kenemans P
   • Yedema CA
   • Hilgers JHM
   • Massuger LFAG
   • Verheijen RHM
   • Thomas CMG
   • Poels LG
   Clinical applications of monoclonal antibodies against ovarian cancer-associated antigens.
   Eur J Obstet Gynecol Reprod Biol. 1988; 29: 207-218
   • Google Scholar
3. • Hilgers J
   • Zotter S
   • Kenemans P
   Polymorphic epithelial mucin and CA 125-bearing glycoprotein in basic and applied carcinoma research.
   Cancer Rev. 1988; 11/12: 1-10
   • Google Scholar
4. • Bast R
   • Feeney M
   • Lazarus H
   • Nadler L
   • Colvin R
   • Knapp R
   Reactivity of a monoclonal antibody with human ovarian carcinoma.
   J Clin Invest. 1981; 68: 1331-1337
   • Google Scholar
5. • Poels LG
   • Peters D
   • Van Megen Y
   • Vooijs GP
   • Verheijen RHM
   • Willemen A
   • Van Niekerk C
   • Jap P
   • Mungyer G
   • Kenemans P
   Monoclonal antibody against human ovarian tumor-associated surface antigens.
   J Natl Cancer Inst. 1986; 76: 781-791
   • Google Scholar
6. • Baak J
   • Chan K
   • Stolk J
   • Kenemans P
   Prognostic factors in Borderline and invasive ovarian tumors of the common epithelial type.
   Pathol Res Pract. 1987; 182: 755-774
   • Google Scholar
7. • Kühnel R
   • Rao BR
   • Poels LG
   • Delemarre JFM
   • Kenemans P
   • Stolk JG
   Multiple parameter analyses of human ovarian cancer: morphology, immunohistochemistry, steroid hormone receptors and aromatase.
   Anticancer Res. 1988; 8: 281-286
   • Google Scholar
8. • Boerman OC
   • Van Niekerk CC
   • Makkink WK
   • Hanselaar AGJM
   • Kenemans P
   • Poels LG
   A comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens.
   Int. J. Gynecol. Pathol. 1990; (in press)
   • Google Scholar
9. • Kenemans P
   • Bast RC
   • Yedema CA
   • Price HR
   • Hilgers J
   CA 125 and polymorph epithelial mucin as serum tumor markers.
   Cancer Rev. 1988; 11/12: 119-144
   • Google Scholar
10. • Henzen-Logmans SC
    • Schipper NW
    • Poels LG
    • Stolk K
    • Kenemans P
    • Meijer CJLM
    Statistical evaluation of antigen profiles in the differential diagnosis between colonic and ovarian adenocarcinomas.
    J Clin Pathol. 1988; 41: 644-649
    • Google Scholar
11. • Bast RC
    • Klug TL
    • St John E
    • Jenison E
    • Niloff JM
    • Lazarus H
    • Berkowitz RS
    • Leavitt T
    • Griffiths T
    • Parker L
    • Zurawski VC
    • Knapp RC
    A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
    New Engl J Med. 1983; 309: 883-887
    • Google Scholar
12. • Zurawski VR
    • Knapp RC
    • Einhorn N
    • Kenemans P
    • Mortel R
    • Ohmi K
    • Bast RC
    • Ritts RE
    • Malkasian G
    An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma.
    Gynecol Oncol. 1988; 30: 7-14
    • Google Scholar
13. • Yedema CA
    • Massuger L
    • Hilgers J
    • Servaas J
    • Poels L
    • Thomas C
    • Kenemans P
    Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA 125 and CA 15.3 serum assays.
    Int J Cancer. 1988; : 61-67
    • Google Scholar
14. • Verheijen RHM
    • Massuger LFAG
    • Kenemans P
    • Haisma HJ
    • Epenetos AA
    Polymorphic epithelial mucin and CA 125-bearing glycoprotein as targets for imaging and therapy with monoclonal antibodies.
    Cancer Rev. 1988; 11/12: 145-172
    • Google Scholar
15. • Kenemans P
    • Massuger LFAG
    • Verheijen RHM
    • Claessens RAMJ
    • Corstens FHM
    Monoclonal antibody based tumor imaging in ovarian cancer.
    in: II ed. Gynecological Cancer. vol. 3. Parthenon Publishing Group, Lancaster, U.K1989: 49-55
    • Google Scholar
16. • Chantal JF
    • Fumoleau P
    • Saccavini JC
    • Thedrez P
    • Curtet C
    • Bianco-Arco A
    • Chetanneau A
    • Peltier P
    • Kremer M
    • Guillard Y
    Immunoscintigraphy of recurrences of gynecologic carcinomas.
    J Nucl Med. 1987; 28: 1807-1819
    • Google Scholar
17. • Hunter RE
    • Boherty S
    • Griffin TW
    • Gionet M
    • Hnatowich DJ
    • Bianco JA
    • Dielon MB
    Use of ¹¹¹In-labeled OC 125 monoclonal antibody in the detection of ovarian carcinoma.
    Gyn Oncol. 1987; 27: 325-337
    • Google Scholar
18. • Haisma HJ
    • Mosely KR
    • Bataille A
    • Griffiths TC
    • Knapp RC
    Distribution and pharmacokinetics of radiolabeled monoclonal antibody OC 125 after intravenous and intraperitoneal administration in gynecologic tumors.
    Am J Obstet Gynecol. 1988; 159: 843-848
    • Google Scholar
19. • Barzen G
    • Mayr AC
    • Langer M
    • Becker R
    • Cordes M
    • Zwicker C
    • Koppenhagen K
    • Felix R
    Radioimmunoscintigraphy of ovarian cancer with ¹³¹I-labeled OC 125 antibody fragments.
    Eur J Nucl Med. 1989; 15: 42-48
    • Google Scholar
20. • Epenetos AA
    • Lavender JP
    • Kenemans P
    • Poels LG
    Early results of the monoclonal antibody OV-TL 3 in specific detection of ovarian cancer.
    J Clin Oncol. 1987; 5: 160
    • Google Scholar
21. • Massuger L
    • Van den Broek W
    • Boerman O
    • Buijs O
    • Buijs W
    • Claessens R
    • Verheijen R
    • Poels L
    • Schijf Ch
    • Van Hoesel Q
    • Kenemans P
    • Corstens F
    Pharmacokinetics and biodistribution of ¹¹¹In-labeled monoclonal antibody (OV-TL 3) in ovarian cancer patients.
    (Abstracts Congress)in: II ed. Eur J Nucl Med. 15. The European Association of Nuclear Medicine, Strasbourg1989: 448 (1989)
    • Google Scholar
22. • Kenemans P
    • Massuger L
    • Claessens R
    • Verheijen R
    • Poels L
    • Schijf C
    • Van Hoesel Q
    • Yedema C
    • Roos J
    • Teule G
    • Vermorken J
    • Corstens F
    Immunolocalisation in ovarian cancer patients using the new monoclonal antibody, OV-TL 3.
    in: Abstracts 2nd Meeting International Gynecology and Cancer Society, Toronto1989: 31
    • Google Scholar
23. • Buist MR
    • Roos JC
    • Golding RP
    • Burger CW
    • Vermorken JB
    • Lingen AV
    • Baak JPA
    • Hilgers J
    • Kenemans P
    Comparison of immunoscintigraphy (¹¹¹In-OV-TL 3-F(ab′)2) with other diagnostic methods in the detection of tumor deposits in ovarian carcinoma patients.
    in: International Conference on Monoclonal Antibody Immunoconjugates for Cancer. 1990 (Abstr San Diego, March 15–17)
    • Google Scholar
24. • Poels LG
    • Kenemans P
    A new monoclonal antibody (OV-TL 3) against human ovarian carcinoma, that does not react with circulating tumor antigens.
    in: Abstracts of Advances in the Applications of Monoclonal Antibodies in Clinical Oncology. II ed. Br J Cancer. 54. 1987: 529
    • Google Scholar
25. • Haisma HJ
    • Knapp RC
    • Battaille A
    • Stradtman EW
    • Zurawski VR
    Antibody-antigen complex formation following injection of ¹³¹I-labeled OC 125 monoclonal antibody F(ab′)₂ fragments into patients with ovarian carcinoma.
    Int J Cancer. 1987; 40: 758-762
    • Google Scholar
26. • Mosely K
    • Battaille A
    • Knapp RC
    • Haisma HJ
    Localization of radiolabelled F(ab′)2 fragments of monoclonal antibodies in nude mice bearing intraperitoneally growing human ovarian cancer xenografts.
    Int J Cancer. 1988; 42: 368-372
    • Google Scholar

27. Boerman O, Massuger L, Makkink K, Thomas C, Kenemans P, Poels L. Comparative in vitro characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies, submitted for publication.

    • Google Scholar

28. Massuger LFAG, Boerman OC, Kenemans P, Poels LG, Claessens RAMJ, Verheijen RHM, Van den Broek W, Corstens FHM. Biodistribution of ¹²⁵I- and ¹¹¹In-labeled OV-TL 3 intact antibodies and F(ab′)2 fragments in tumor-bearing athymic mice, submitted for publication.

    • Google Scholar